Abstract
Objectives
Prostate carcinoma is a major health problem, and routine imaging shows only modest
results in detecting and restaging clinically localized prostate cancer recurrence.
Recent studies have shown promise of radiolabeled analogues of choline for positron
emission tomography (PET) scans in patients of biochemical recurrence and that sequentially
incremental Fluorocholine (FCH) uptake is associated with malignancy, whereas decreasing tracer activity suggests
a benign aetiology. However, this pattern of tracer uptake has not been fully validated,
and no standardized 18F-Fluorocholine (18F-FCH) scan protocol is in place yet. This study aimed to better define the role of dual-phase
18F-FCH PET/computed tomography (CT) imaging using retrospective masked reading focusing
on detection of locoregional recurrence/metastasis in patients with biochemical failure
after definitive local primary treatment.
Methods
A total of 32 subjects were enrolled during the period 04/2010 to 05/2014 with histologically
proven prostate cancer that was treated with curative intent and had biochemical recurrence.
Early scans and delayed imaging of the pelvis were graded separately by blinded readers.
Final evaluation using the combination of information from dual-phase studies as a
“summation scan” was also performed. Maximum standardized uptake value was computed
using regions of interest constructed over focal hyperactivity. Calculations were
performed using Statistical Product and Service Solutions, Version 20 for Windows.
A composite reference consisting of histopathology, correlation with other imaging,
or serum prostate specific antigen (PSA) trend with clinical follow-up of at least
6 months was used to determine the true disease status of the patient.
Results
Early-phase pelvis imaging sensitivity and specificity were calculated to be 73.1%
and 90.9%, respectively. Late-phase pelvis imaging sensitivity and specificity were
80.8% and 100%, respectively. Summation scan sensitivity and specificity were 76.9%
and 100%, respectively. The odds ratio of having recurrent disease with an uptrend
of SUVmax on dual-phase imaging was 33.3. The optimal cutoff value of PSA was 1.85 ng/mL with 80% sensitivity and 62.5% specificity.
Conclusions
Single late-phase FCH PET/CT imaging is a reliable scan modality which can detect
sites of disease at low levels of PSA which still fulfil the criteria of biochemical
recurrence. This will allow clinicians to identify sites for potential biopsy or start
locoregional treatment.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of prostate cancer.Asian Pac J Cancer Prev. 2015; 16: 5137-5141
- Current controversies in the management of biochemical failure in prostate cancer.Clin Adv Hematol Oncol. 2012; 10: 716-722
- Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition.J Clin Oncol. 2006; 24: 3973-3978
- Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
- Imaging prostate cancer: a multidisciplinary perspective.Radiology. 2007; 243: 28-53
- Novel tracers and their development for the imaging of metastatic prostate cancer.J Nucl Med. 2008; 49: 2031-2041
- Imaging of prostate cancer.Curr Opin Oncol. 2007; 19: 259-264
- False-negative bone scan and choline PET/CT study in a case of prostate cancer: the pitfall of the small cell prostate carcinoma variant.World J Nucl Med. 2012; 11: 75-78
- Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer.Nucl Med Commun. 2014; 35: 221-230
- A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.Nucl Med Commun. 2013; 34: 935-945
- The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systemic review and meta-analysis.Eur Urol. 2013; 64: 106-117
- Choline PET or PET/CT and biochemical relapse of prostate cancer: a systemic review and meta-analysis.Clin Nucl Med. 2013; 38: 305-314
- 18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.Eur J Nucl Med Mol Imaging. 2006; 33: 1387-1398
- Localisation of primary prostate cancer with dual-phase 18F-flurocholine PET.J Nucl Med. 2006; 47: 262-269
- Dual-phase PET-CT to differentiate [18F]fluoromethylcholine uptake in reactive and malignant lymph nodes in patients with prostate cancer.PLoS One. 2012; 7: e48430
- Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading.Q J Nucl Med Mol Imaging. 2011; 55: 448-457
- Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.J Nucl Med. 2001; 42: 1412-1417
- The impact of urinary excretion of (18)F-labeled choline analogs.J Nucl Med. 2007; 48: 1225
- Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.Cancer Res. 2001; 61: 110-117
- Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers.J Nucl Med. 2001; 42: 1805-1814
- Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.J Urol. 2002; 168: 273-280
- Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.J Med Imaging Radiat Oncol. 2010; 54: 325-332
- Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.Eur J Nucl Med Mol Imaging. 2008; 35: 1766-1774
- The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.Mol Imaging Biol. 2009; 11: 446-454
- Optimising (18)F –choline PET/CT acquisition protocol in prostate cancer patients.N Am J Med Sci. 2012; 4: 416-420
- Three-phase 18F-flurocholine PET/CT in the evaluation of prostate cancer recurrence.Nuklearmedizin. 2009; 48: 1-9
- Choline PET/CT for imaging prostate cancer: an update.Ann Nucl Med. 2013; 27: 581-591
- New acquisition protocol of 18F-choline PET/CT in prostate cancer patients: review of the literature about methodology and proposal of standardization.Biomed Res Int. 2014; 2014: 10215650
- Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.J Urol. 2006; 176 ([discussion 8–9]): 2014-2018
- 18F-choline, 11C-choline, and 11C-acetate PET/CT: a comparative analysis for imaging prostate cancer patients.Eur J Nucl Med Mol Imaging. 2013; 40: S18-S27
- Prostate cancer topography and patterns of lymph node metastasis.Am J Surg Pathol. 2010; 34: 1862-1867
- Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients.J Urol. 2007; 177: 916-920
Article info
Publication history
Published online: January 05, 2016
Accepted:
December 29,
2015
Received in revised form:
December 14,
2015
Received:
September 7,
2015
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.